|Articles|June 15, 2018
Greenphire Expands Flexibility of eClinicalGPS to Increase CRO and Sponsor Control
Advertisement
KING OF PRUSSIA, Pa., June 13, 2018 /PRNewswire/ -- Greenphire , the global leader in financial software for clinical trials, today announced enhancements to its eClinicalGPS site payment solution, expanding configuration and administration options, providing CROs and sponsors unmatched capability, flexibility, and control. With these enhancements, Greenphire is positioned to take an even more collaborative and strategic role with CRO and sponsor partners in identifying the delivery model, whether self-service, full service, or somewhere in between, to maximize the ROI in site payment automation.
Increasing trial complexity and expanding industry emphasis on site centricity are contributing to the rapid evolution of grant payment management. The latest enhancements to Greenphire's SaaS-based eClinicalGPS make it possible for more sponsors and CROs to automate their investigator payment processes globally.
"A one-size-fits-all approach to site payments is not scalable or sustainable in today's clinical research landscape," said Jim Murphy, CEO of Greenphire. "Sponsors and CROs focused on optimizing payment processes need advanced financial features which can be configured to support their unique workflows, as well as those of their investigative sites around the world."
Among the new features and functionality supporting greater sponsor and CRO payment flexibility are:
- Customizable payment execution models, empowering the sponsor or CRO to choose if and where they execute payments
- Funding flexibility, giving sponsors and CROs that use eClinicalGPS the ability to execute payments to fund and pay in any currency
- Dynamic Payment Parsing, enabling sites to simplify payment administration to their contract staff
eClinicalGPS is the site payment software of choice for global sponsors and CROs looking to automate investigator grant payments enterprise-wide. Backed by a team of experts in global financial software development for clinical research that delivers measurable ROI, the SaaS-based solution leads the industry in technology sophistication and adoption around the world.
For more information, or to schedule a demo, contact sales@greenphire.com .
About Greenphire
Greenphire is the global leader in clinical trial payment automation. Greenphire is exclusively focused on optimizing clinical trial performance by streamlining payment processes from sponsors and CROs to sites and patients. The choice of industry leaders worldwide, Greenphire supports site centricity and sustainability, increases patient engagement and retention, and provides more comprehensive financial data, resulting in better trials. Learn more atwww.greenphire.com .
Greenphire is the global leader in clinical trial payment automation. Greenphire is exclusively focused on optimizing clinical trial performance by streamlining payment processes from sponsors and CROs to sites and patients. The choice of industry leaders worldwide, Greenphire supports site centricity and sustainability, increases patient engagement and retention, and provides more comprehensive financial data, resulting in better trials. Learn more at
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025
- Vabysmo Shows Long-Term Efficacy and Safety in Wet AMD, PCV Patients
September 12th 2025
- Latest NIMBLE Study Results Highlight Progress in gMG Research
September 12th 2025
- ACT Brief Episode 8: Expert Insights on the Future of Obesity Drug Trials
September 11th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Fast Tracks Sanofi’s Intravitreal Gene Therapy for Neovascular Age-Related Macular Degeneration
2
Phase III BRUIN CLL-313 Trial Finds Jaypirca Extends Progression-Free Survival in Treatment-Naïve CLL/SLL
3
Latest NIMBLE Study Results Highlight Progress in gMG Research
4
ACT Brief Episode 8: Expert Insights on the Future of Obesity Drug Trials
5